Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Genentech has announced updates following the FDA’s Oncologic Drugs Advisory Committee (ODAC) meeting regarding Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) for treating relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). This combination could offer a significant survival benefit for patients who are not candidates for autologous stem cell transplant (ASCT). Source: […]